Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma,

Loading news article.

Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma, | WAPE

Summit Therapeutics Announced Opening Of Global Phase II SMT112-216 Trial Of Ivonescimab Alone Or Combined With Cadonilimab Or Ipilimumab In Previously Untreated Advanced Clear Cell Renal Cell Carcinoma,

Article summary

Related companies

Comments —